Liver Metastases Clinical Trials

16 studies are recruiting for liver metastases in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis

   The goal of this clinical trial is to learn if histotripsy plus chemotherapy works to treat unresectable, bilobar liver- confined colorectal cancer liver metastasis (CRLM). The main question this clinical trial aims to answer is: • Does the management of this condition with uninterrupted palliative…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT07044362 on ClinicalTrials.gov

2. Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

   This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients wit…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UW Hospital and Clinics, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT07281924 on ClinicalTrials.gov

3. Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

   This Phase 1b/2 trial will evaluate the safety and efficacy of neoadjuvant immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) subjects with resectable liver metastases.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Run by

   Dan Feng

   See if you can join NCT07277322 on ClinicalTrials.gov

4. HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer

   This is a pilot and feasibility study assessing the role of quantitative multiparametric MRI and blood-based biomarkers for the measurement of liver function in patients receiving radiation therapy for liver cancer, including hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver metastases r…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Montefiore Medical Center, The Bronx, New York

   Run by

   Montefiore Medical Center

   See if you can join NCT06899152 on ClinicalTrials.gov

5. DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

   The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE/HVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE. This collaborative registry focuses on identifying associations between baseline clinical/imaging parame…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Rush University Medical Center, Chicago, Illinois

   Locations

   31 in total

   Run by

   Maastricht University Medical Center

   See if you can join NCT07717437 on ClinicalTrials.gov

6. ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases

   To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05062317 on ClinicalTrials.gov

7. OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases

   The purpose of this trial is to identify a safe maximum tolerated dose level for MRI-guided Stereotactic Body Radiation Therapy (SBRT) treatment of bowel and liver metastases, respectively. Eligible participants will be on study for up to 12 months.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Wisconsin, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT04020276 on ClinicalTrials.gov

8. Proton Therapy in the Treatment of Liver Metastases

   Local control of hepatic metastases appears to be a major determinant of overall survival. However, many patients are not suitable for resection due to medical or surgical reasons. Therefore, there is an important role for a treatment that can provide the equivalent of tumor resection with minimal …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Loma Linda University Medical Center, Loma Linda, California

   Run by

   Loma Linda University

   See if you can join NCT01697371 on ClinicalTrials.gov

9. Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

   The goal of this clinical trial is to to learn about different combinations of immunotherapy in patients with colorectal cancer whose cancer has spread to their liver and are planning to have surgery to remove tumor metastases from their liver. The main questions it aims to answer are: * whether th…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT06300463 on ClinicalTrials.gov

10. Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment

    This study will see whether collecting and analyzing needle biopsy samples from cancer liver metastases after a tumor ablation procedure will be able to identify cancer cells that are still alive. The results of these biopsies could help determine the next treatment for your cancer, but the biopsie…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04143516 on ClinicalTrials.gov

11. The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

    The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpos…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Allegheny Health Network, Pittsburgh, Pennsylvania

    Locations

    18 in total

    Run by

    UMC Utrecht

    See if you can join NCT04075305 on ClinicalTrials.gov

12. Promoting Immunotherapy Efficacy With Low-Dose Liver RT

    The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Cincinnati Medical Center, Cincinnati, Ohio

    Run by

    Jordan Kharofa

    See if you can join NCT07225036 on ClinicalTrials.gov

13. A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer

    The researchers are doing this study to see if one session of high-dose contrast-enhanced MRI-guided SBRT (stereotactic body radiation therapy) is effective for colorectal cancer that has spread to the liver. The researchers will evaluate how well the study treatment can prevent the liver metastasi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06130280 on ClinicalTrials.gov

14. REGULUS: MRI-guided Adaptive SABR for Liver Cancers

    Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Stanford University, Palo Alto, California

    Run by

    Stanford University

    See if you can join NCT07223307 on ClinicalTrials.gov

15. Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

    This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer (ES-SCLC) with liver metastases. The main questions it aims to answer are: …

    Stage

    Phase 2

    Ages

    Any age

    Site

    Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

    Locations

    3 in total

    Run by

    Kamya Sankar

    See if you can join NCT05588388 on ClinicalTrials.gov

16. Stereotactic Magnetic Resonance Guided Radiation Therapy

    This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Ph…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Brigham & Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04115254 on ClinicalTrials.gov